Anteris Technologies Global Corp. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
AVR Nasdaq 3840 anteristech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Anteris Technologies Global Corp.

A new valve, a new playbook: How Anteris is trying to reshape a $10B heart market - Apr 1st, 2026 9:47 pm
Truffle Capital Unveils the First Edition of the Truffle MedTech 10 - Mar 18th, 2026 1:00 am
Anteris Technologies Global CEO Touts DurAVR Redesign, Durability Claims and TAVR Market Strategy - Mar 12th, 2026 6:35 am
Anteris Technologies Global Highlights DurAVR TAVR Data, PARADIGM Pivotal Trial Plans at TD Cowen Conference - Mar 5th, 2026 3:03 am
Anteris reports US$77.8m 2025 net operating cash outflow as PARADIGM trial gets underway - Feb 26th, 2026 4:41 pm
Anteris Reports 2025 Financial Results and Provides Corporate Update - Feb 26th, 2026 4:00 pm
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays - Feb 23rd, 2026 4:30 am
Anteris Technologies price target lowered to $15 from $20 at Lake Street - Jan 24th, 2026 7:01 am
Retail investors who hold 25% of Anteris Technologies Global Corp. (ASX:AVR) gained 41%, institutions profited as well - Jan 23rd, 2026 1:17 pm
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises - Jan 22nd, 2026 2:02 pm
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock - Jan 22nd, 2026 2:01 pm
Anteris Technologies announces $200M public offering to fund clinical growth - Jan 22nd, 2026 9:28 am
Medtronic to buy up to $90M stake in heart valve developer Anteris - Jan 21st, 2026 3:50 am
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering - Jan 20th, 2026 8:53 pm
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic - Jan 20th, 2026 2:01 pm
Investors in Anteris Technologies Global (ASX:AVR) have unfortunately lost 75% over the last three years - Nov 19th, 2025 3:10 pm
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves - Nov 17th, 2025 4:00 am
Anteris Announces Results for the Third Quarter of 2025 - Nov 12th, 2025 3:52 pm
FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”) - Nov 3rd, 2025 5:00 am
Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year - Oct 28th, 2025 4:08 pm